PVLAHealthcare · BiotechnologyThe 15 Wall Street analysts covering Palvella Therapeutics, Inc. hold a median 12-month price target of $232 — +54.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 18 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Palvella Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PVLA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +54.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 May 2026 | Chardan Capital | Maintains | Buy | $240 |
| 21 May 2026 | Stephens & Co. | Reiterates | Overweight | $220 |
| 12 May 2026 | Stephens & Co. | Initiates | Overweight | — |
| 31 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 24 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 25 Feb 2026 | BTIG | Maintains | Buy | — |
| 25 Feb 2026 | Mizuho | Maintains | Outperform | — |
| 24 Feb 2026 | Chardan Capital | Maintains | Buy | — |
| 24 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Jan 2026 | BTIG | Reiterates | Buy | — |
| 16 Jan 2026 | BTIG | Reiterates | Buy | — |
| 7 Jan 2026 | Mizuho | Initiates | Outperform | — |
| 16 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 16 Dec 2025 | Chardan Capital | Maintains | Buy | — |
| 16 Dec 2025 | TD Cowen | Maintains | Buy | — |
| 16 Dec 2025 | Truist Securities | Maintains | Buy | — |
| 15 Dec 2025 | BTIG | Maintains | Buy | — |
| 15 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Dec 2025 | BTIG | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PVLA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Palvella Therapeutics, Inc. returned +155.0% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 49% of US stocks
Cheaper than 9% of US stocks
Cheaper than 95% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Palvella Therapeutics, Inc. has a market value of $2.2B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$61.7M.
Free cash flow in the twelve months to 30 June 2026: −$36.5M.
Trailing P/E: 13.7×; forward P/E: −20.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Palvella Therapeutics, Inc. employs 29 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Palvella Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Palvella Therapeutics announced the appointment of James R. Treat, M.D., who brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations, and angiokeratomas.
Why it matters — A PVLA watcher would care because this appointment adds specialized dermatologic expertise relevant to the company's therapeutic focus areas.
Palvella Therapeutics announced that CEO Wes Kaupinen will participate in two upcoming healthcare investor conferences. The company is a clinical-stage biopharmaceutical firm focused on developing therapies for rare skin diseases and vascular malformations.
Why it matters — A PVLA watcher would care because the CEO's participation in investor conferences provides opportunities for the company to present its pipeline and strategies to the investment community.
Palvella Therapeutics completed the rolling submission of its New Drug Application to the FDA for QTORIN rapamycin, intended for the treatment of microcystic lymphatic malformations. The therapy has the potential to become the first FDA-approved treatment for this condition, which affects an estimated more than 30,000 pediatric and adult patients in the U.S.
Why it matters — This milestone moves Palvella closer to potentially securing the first FDA-approved therapy for microcystic lymphatic malformations, a significant commercial opportunity for the company.
Palvella Therapeutics is advancing QTORIN rapamycin for microcystic lymphatic malformations, having posted positive Phase 3 SELVA data and begun a rolling NDA submission. The company plans to expand QTORIN across multiple mTOR-driven dermatological indications, supported by a recent $230M equity raise.
Why it matters — PVLA watchers would care because the first approval and a recent $230M equity raise could help Palvella build a repeatable multi-indication commercial platform while mitigating typical small-biotech funding risks.
Palvella Therapeutics is advancing topical therapies for rare skin diseases and vascular malformations lacking FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations. The item notes a 2027 approval target as the rare-disease pipeline expands.
Why it matters — A PVLA watcher would care because the planned NDA submission for QTORIN rapamycin brings the company's lead candidate closer to a milestone in an area with no FDA-approved treatments.
The 15 Wall Street analysts covering Palvella Therapeutics, Inc. have a median 12-month price target of $232, with estimates ranging from $205 to $270. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Palvella Therapeutics, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palvella Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 18 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 18 Sept 2026, Palvella Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +54.1% from the last close, and Ticker Nerd's factor model ranks Palvella Therapeutics, Inc. 32 out of 100 as at 18 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Palvella Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PVLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $205 to $270 over the next 12 months.
Palvella Therapeutics, Inc. returned +155.0% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, rare skin diseases and vascular malformations with no FDA-approved treatment options.
The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Palvella Therapeutics Appoints James R. Treat, M.D.". Palvella Therapeutics announced the appointment of James R. Treat, M.D., who brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations, and angiokeratomas.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, rare skin diseases and vascular malformations with no FDA-approved treatment options. The company centers its work on dermatology-focused rare disease programs, using its proprietary QTORIN platform to create topical therapies designed for localized delivery in difficult-to-treat conditions. Its current pipeline includes product candidates being studied for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas, reflecting a focus on genetically driven and orphan skin disorders. Palvella Therapeutics serves the rare disease and specialty dermatology markets, where targeted medicines can address conditions that are often chronic, burdensome, and underserved by existing therapies. Palvella Therapeutics, Inc. is headquartered in Wayne, Pennsylvania.
CEO Mr. Wesley H. Kaupinen · 29 employees · United States · https://palvellatx.com
